DRG 392 Overview

DRG 392 covers hospitalizations for esophagitis, gastroenteritis, and a range of miscellaneous digestive disorders without a Major Complication or Comorbidity. Typical cases include inflammatory or infectious conditions of the esophagus and stomach, acute gastroenteritis, and other non-severe digestive diagnoses that do not trigger higher-severity payment. This Diagnosis-Related Group is important for Medicare payment because it groups clinically related lower-severity digestive admissions into a single prospective payment rate, affecting hospital reimbursement and resource classification. Accurate coding and documentation determine assignment to this Diagnosis-Related Group rather than higher-severity groups.

Payer rates range from a low of $1.1K (BCBS p25) up to $27K (Anthem max) across the commercial benchmarks, with mean rates clustered between roughly $7.2K and $13K depending on payer. Anthem and Aetna show the highest upper-end maximums, while BCBS reports the lowest median-level values. The widest spread between payer extremes is between the $1.1K benchmark point and the $27K maximum shown in the table and chart below.

The CMS 2023 data represent national Medicare fee-for-service inpatient payments reported under the CMS Provider Utilization and Payment Data program. The table below shows average total payment ($7.5k), average submitted covered charges ($38.3k), average Medicare payment amount ($5.5k), and total discharges (91.1k).

• Acute management interventional studies: Trials testing rapid symptom control strategies for hospitalized patients presenting with severe esophagitis, gastroenteritis, or other acute digestive disorders (for example, studies of antiemetic protocols, IV rehydration regimens, or endoscopic hemostasis approaches). These studies enroll patients at presentation or during the inpatient stay to evaluate short‑term clinical endpoints such as time to symptom resolution, need for intensive care, length of stay, and readmission within 30 days. Results inform inpatient care pathways and resource use, helping providers optimize acute treatment and payers anticipate and manage short‑term costs associated with this DRG.
• Comparative effectiveness and diagnostics studies: Prospective or pragmatic trials comparing diagnostic algorithms and medical management strategies for common non‑MCC digestive conditions (for instance, comparing early endoscopy versus conservative management in esophagitis with bleeding risk, or stool testing strategies for infectious gastroenteritis). These studies focus on heterogenous adult populations admitted for digestive complaints to determine which approaches yield better diagnostic yield, fewer complications, and lower unnecessary utilization. Findings guide evidence‑based selection of tests and treatments, influencing provider decision making and payer coverage policies to reduce variation and inappropriate use of high‑cost services.
• Post‑discharge outcomes and health services research: Cohort studies and randomized implementation trials measuring post‑discharge outcomes such as 30‑ and 90‑day readmissions, outpatient follow‑up adherence, quality of life, and costs for patients hospitalized with esophagitis, gastroenteritis, or other non‑MCC digestive disorders. These studies often evaluate transitional care interventions (discharge education, care coordination, telehealth follow‑up) in older adults and patients with comorbidities who are at higher risk of return visits. Results are relevant to hospitals and payers seeking to reduce readmissions, improve outpatient management, and align reimbursement and care pathways for this DRG.